Premium
Inappropriate inhaled corticosteroid prescribing in chronic obstructive pulmonary disease patients
Author(s) -
Harrison Amelia,
Borg Brigitte,
Thompson Bruce,
Hew Mark,
Dabscheck Eli
Publication year - 2017
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13611
Subject(s) - medicine , bronchodilator , copd , guideline , inhaler , medical prescription , pulmonary disease , bronchodilator agents , inhaled corticosteroids , pulmonary function testing , obstructive lung disease , lung function , corticosteroid , intensive care medicine , asthma , physical therapy , anesthesia , lung , pathology , pharmacology
The Australian National Chronic Obstructive Pulmonary Disease ( COPD ) guidelines recommend that inhaled corticosteroids ( ICS ) be reserved for patients with a post‐bronchodilator forced expiratory volume in 1 s ( FEV 1 ) less than 50% predicted and those who experience ≥2 exacerbations in 12 months. In total, 707 COPD patients were identified from the lung function test database at our tertiary hospital; 52.4% of patients with a post‐bronchodilator FEV 1 ≥50% were prescribed an ICS . Significant discordance exists between guideline recommendations and inhaler prescription.